<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00375895</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT 2006-002714-35</org_study_id>
    <secondary_id>LOC/06-05</secondary_id>
    <secondary_id>CIC0203/058</secondary_id>
    <nct_id>NCT00375895</nct_id>
  </id_info>
  <brief_title>Switch From Tacrolimus to Cyclosporin in the Treatment of Recurrent Hepatitis C After Liver Transplantation</brief_title>
  <official_title>Prospective, Open-label, Single Arm Pilot Study Evaluating the Effect on Virological Response of the Switch From Tacrolimus to Cyclosporin Associated With a Peginterferon Alfa-2a / Ribavirin Bitherapy, in Non-responder or With Recurrent VHC+ Disease Liver Transplanted Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rennes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Rennes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In France, 50% of hepatitis C virus carriers develop chronic clinical hepatitis, which may&#xD;
      lead to cirrhosis and liver transplantation. Transplant infection by hepatitis C virus is&#xD;
      constant after transplantation and recurrence causes chronic liver disease in 50 to 80% of&#xD;
      cases. The aim of this study is to assess the efficacy of cyclosporin on C virological&#xD;
      response. Patients included in the Transpeg 1 study and non-responder or with a recurrent&#xD;
      disease will be switched from their tacrolimus therapy to cyclosporin, in association with a&#xD;
      1 year peginterferon alfa-2a / ribavirin bitherapy. Efficacy will be assessed by the&#xD;
      percentage of patients with a negative qualitative PCR after 19 months of cyclosporin&#xD;
      treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In France, 50% of hepatitis C virus carriers develop chronic clinical hepatitis, which may&#xD;
      lead to cirrhosis and liver transplantation. Transplant infection by hepatitis C virus is&#xD;
      constant after transplantation. A main factor determining the severity of recurrent hepatitis&#xD;
      C after transplantation may be immunosuppression. Thus optimization of immunosuppressive&#xD;
      regimens might be a key aspect to improve the prognosis of chronic hepatitis C in&#xD;
      transplanted patients. The two most frequently used immunosuppressive drugs are cyclosporin&#xD;
      and tacrolimus. However, it has been shown that virus replication could be inhibited by&#xD;
      cyclosporin, through the blockade of cyclophilins, decreasing hepatitis C viral load and&#xD;
      improving liver function. These effects were not found with tacrolimus.&#xD;
&#xD;
      The aim of our study is to assess the efficacy on C virological response of the switch from&#xD;
      tacrolimus to cyclosporin associated with a peginterferon alfa-2a / ribavirin bitherapy, in&#xD;
      non-responder or with a recurrent VHC+ disease liver transplanted patients.&#xD;
&#xD;
      Patients will receive a 19 month cyclosporin treatment, associated during 12 months with a&#xD;
      peginterferon alfa-2a / ribavirin bitherapy. Efficacy will be assessed by the percentage of&#xD;
      patients with a negative qualitative PCR after 19 months of cyclosporin treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Insufficient enrollment&#xD;
  </why_stopped>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prolonged virological response</measure>
    <time_frame>19 months</time_frame>
    <description>Percentage of patients with a negative qualitative PCR, 19 months after the initiation of cyclosporin treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Virological response 4, 7 and 13 months after the initiation of cyclosporin treatment</measure>
    <time_frame>4, 7 and 13 months</time_frame>
    <description>Percentage of patient with negative or decreased quantitative PCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histological response: METAVIR score at 19 months</measure>
    <time_frame>19 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biological response: liver function at 4, 7, 13 and 19 months</measure>
    <time_frame>4, 7, 13 and 19 months</time_frame>
    <description>Transaminases, gammaGT, alcalin phosphatase, total bilirubin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of acute or chronic graft rejection at 19 months</measure>
    <time_frame>19 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of death, graft loss and retransplantation at 13 and 19 months</measure>
    <time_frame>13 and 19 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function at 4, 7, 13 and 19 months</measure>
    <time_frame>4, 7, 13 and 19 months</time_frame>
    <description>Creatinin clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment discontinuation at 4, 7, 13 and 19 months</measure>
    <time_frame>4, 7, 13 and 19 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events (cancers in particular).</measure>
    <time_frame>19 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <condition>Evidence of Liver Transplantation</condition>
  <arm_group>
    <arm_group_label>Ciclosporin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ciclosporin</intervention_name>
    <description>ciclosporin administered orally twice a day, at the initial dosing of 2.5 mg/kg/d, adjusted to obtain a C2 concentration of 600 ng/ml associated with the usual ribavirin and PEGinterferon bitherapy.</description>
    <arm_group_label>Ciclosporin</arm_group_label>
    <other_name>CsA</other_name>
    <other_name>Cyclosporin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults aged 18 or over,&#xD;
&#xD;
          -  Who had been included in the Transpeg 1 study,&#xD;
&#xD;
          -  Non-responders after a three month peginterferon alfa-2a / ribavirin bitherapy or with&#xD;
             a recurrent disease during the Transpeg 1 maintenance phase, whatever the&#xD;
             randomization group (ribavirin or placebo),&#xD;
&#xD;
          -  With a positive qualitative PCR at inclusion,&#xD;
&#xD;
          -  With a METAVIR histologic score of 1 or more on the last biopsy (done within the 6&#xD;
             months preceding inclusion),&#xD;
&#xD;
          -  Treated with tacrolimus for at least 6 months prior to inclusion,&#xD;
&#xD;
          -  Having given a written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Treatment with peginterferon or ribavirin within the 6 months preceding inclusion,&#xD;
&#xD;
          -  Severe hepatocellular failure or decompensated cirrhosis,&#xD;
&#xD;
          -  Acute graft rejection within the two months preceding inclusion, or signs of chronic&#xD;
             rejection on the last biopsy, or retransplantation since inclusion in the Transpeg 1&#xD;
             study,&#xD;
&#xD;
          -  Treatment with cyclosporin for more than 6 months during the 24 months preceding&#xD;
             inclusion,&#xD;
&#xD;
          -  Treatment with a mTOR inhibitor or with another investigational immunosuppressive&#xD;
             drug,&#xD;
&#xD;
          -  Positive serology for HIV or HBV,&#xD;
&#xD;
          -  Cancer (or history of other malignancy during the last 5 years) except patients&#xD;
             transplanted for hepatocellular carcinoma and basocellular or excised spinocellular&#xD;
             carcinoma,&#xD;
&#xD;
          -  Serious concomitant disease or acute or chronic disorder, other than the current&#xD;
             transplant, treated with steroids,&#xD;
&#xD;
          -  Serious cardiac pathology within the last 6 months,&#xD;
&#xD;
          -  Women with ongoing pregnancy or breast-feeding,&#xD;
&#xD;
          -  Serious chronic renal failure (creatinine clearance &lt; 30 ml/mn),&#xD;
&#xD;
          -  Haemoglobin &lt; 10 g/dl, platelets &lt; 50 000/mm3 or neutrophils &lt; 1000 / mm3,&#xD;
&#xD;
          -  Abnormal TSH values,&#xD;
&#xD;
          -  Inability to cooperate or to communicate with the investigator,&#xD;
&#xD;
          -  Contraindications to ribavirin, peginterferon alfa-2a or cyclosporin.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yvon Calmus, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Cochin, Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eric Bellissant, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>CHU Rennes</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Service d'Hépatologie - Hôpital Jean Minjoz</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Hépatogastroentérologie - Hôpital Beaujon</name>
      <address>
        <city>Clichy</city>
        <zip>92118</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Hépatologie et Gastroentérologie - CH Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service des Maladies de l'Appareil Digestif - CHRU Claude Huriez</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie Générale - Hôpital Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chirurgie Générale - Hôpital de la Conception</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Hépato-gastro-entérologie - Hôpital Saint Eloi</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chirurgie Viscérale et Digestive - Hôpital de l'Archet</name>
      <address>
        <city>Nice</city>
        <zip>06200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie Générale - Hôpital Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75679</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service des Maladies du Foie - Hôpital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie Générale et Transplantation Multi-organe - Hôpital de la Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Hépato-gastro-entérologie - Hôpital de Rangueil</name>
      <address>
        <city>Toulouse</city>
        <zip>31403</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hépato-Biliaire - Hôpital Paul Brousse</name>
      <address>
        <city>Villejuif</city>
        <zip>94804</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <study_first_submitted>September 12, 2006</study_first_submitted>
  <study_first_submitted_qc>September 12, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2006</study_first_posted>
  <last_update_submitted>March 1, 2012</last_update_submitted>
  <last_update_submitted_qc>March 1, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 2, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cyclosporin</keyword>
  <keyword>Peginterferon</keyword>
  <keyword>Ribavirin</keyword>
  <keyword>Chronic hepatitis C</keyword>
  <keyword>Liver transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

